



Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER⁺HER2⁻ metastatic breast cancer: a phase 1 trial

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-024-03060-0>, published online 1 June 2024

<https://doi.org/10.1038/s41591-024-03129-w>

Published online: 24 June 2024

Toru Mukohara, Yeon Hee Park , David Sommerhalder , Kan Yonemori , Erika Hamilton , Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita , Rachel M. Layman , Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J. Lindeman , Hope S. Rugo , Marlon Liyanage , Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li & Patricia M. LoRusso

In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part 2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig. 5, “(confirmed)” has been removed from both graph legends, which originally read “Best overall response (confirmed)”. In Extended Data Table 1, the title of Table 1B has been corrected from “PF-07248144 dose and DLT relationship” to “Bayesian Logistic Regression Model: Predicted probability of DLT”. These corrections have been made to the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

Author Correction: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-024-02896-w>, published online 26 March 2024

<https://doi.org/10.1038/s41591-024-03128-x>

Published online: 17 June 2024

Anubha Agarwal , Priya M. Mehta , Tyler Jacobson , Nilay S. Shah, Jiancheng Ye, JingJing Zhu, Q. Eileen Wafford, Ehete Bahiru, Angharad N. de Cates, Shah Ebrahim, Dorairaj Prabhakaran, Anthony Rodgers & Mark D. Huffman

In the version of the article initially published, the sentence “The scientific foundation underlying the concept of a fixed-dose combination, or polypill, therapy targeting multiple modifiable ASCVD risk factors was first proposed in patents GB 0100548.7 and GB 008791.6 filed by Nicholas Wald and Malcolm Law in 2000 and discussed in 2001 by a World Health Organization and Wellcome Trust expert group” originally lacked the patent information, which has now been added to the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024